Vincerx: FDA Safe to Proceed Letter for IND Application for Small Molecule-Drug Conjugate

 VIP236 is a first-in-class αVβ3 integrin binder SMDC with the potential to address a broad patient population across multiple solid tumor indications

Preclinical studies with VIP236 demonstrated promising tumor regression in in vivo cancer models

VIP236 first-in-human study in advanced or metastatic solid tumors anticipated to commence in Q1 2023

https://finance.yahoo.com/news/vincerx-pharma-announces-fda-safe-142900852.html